Epithelial phenotype restoring drugs suppress macular degeneration phenotypes in an iPSC model
Ruchi Sharma,Aman George,Malika Nimmagadda,Davide Ortolan,Barbosa-Sabanero Karla,Zoya Qureshy,Devika Bose,Roba Dejene,Genqing Liang,Qin Wan,Justin Chang,Balendu Shekhar Jha,Omar Memon,Kiyoharu Joshua Miyagishima,Aaron Rising,Madhu Lal,Eric Hanson,Rebecca King,Mercedes Maria Campos,Marc Ferrer,Juan Amaral,David McGaughey,Kapil Bharti
DOI: https://doi.org/10.1038/s41467-021-27488-x
IF: 16.6
2021-12-01
Nature Communications
Abstract:Abstract Age-related Macular Degeneration (AMD), a blinding eye disease, is characterized by pathological protein- and lipid-rich drusen deposits underneath the retinal pigment epithelium (RPE) and atrophy of the RPE monolayer in advanced disease stages - leading to photoreceptor cell death and vision loss. Currently, there are no drugs that stop drusen formation or RPE atrophy in AMD. Here we provide an iPSC-RPE AMD model that recapitulates drusen and RPE atrophy. Drusen deposition is dependent on AMD-risk-allele CFH(H/H) and anaphylatoxin triggered alternate complement signaling via the activation of NF-κB and downregulation of autophagy pathways. Through high-throughput screening we identify two drugs, L-745,870, a dopamine receptor antagonist, and aminocaproic acid, a protease inhibitor that reduce drusen deposits and restore RPE epithelial phenotype in anaphylatoxin challenged iPSC-RPE with or without the CFH(H/H) genotype. This comprehensive iPSC-RPE model replicates key AMD phenotypes, provides molecular insight into the role of CFH(H/H) risk-allele in AMD, and discovers two candidate drugs to treat AMD.
multidisciplinary sciences